ReviewDiscover oncology2025
CTLA4 genetic variants influence immune regulation and susceptibility of HPV associated cervical cancer.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cervical cancer remains a significant global health burden, representing one of the leading causes of morbidity and mortality among women. While persistent infection with oncogenic types of Human Papillomavirus (HPV) is the primary risk factor for cervical carcinogenesis, only a subset of infected women progress to malignancy, suggesting that host genetic factors play a critical role in disease susceptibility. This narrative review explores the influence of single nucleotide variants (SNVs) in the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on the risk of HPV-associated cervical cancer, with a focus on the modulation of this immune checkpoint pathway. CTLA-4 is expressed on the surface of T cells and functions as a negative regulator of immune activation. Its genetic variants may influence gene transcription efficiency, protein processing and transport, and/or binding affinity to its B7 ligand, thereby affecting viral clearance and immune surveillance against HPV-transformed cells. Current evidence supports associations between specific CTLA4 SNVs, such as rs5742909 (- 318 C > T), rs231775 (+ 49 A > G) and rs3087243 (+ 6230 G > A), and increased susceptibility to cervical cancer, supporting their potential as prognostic biomarkers and therapeutic targets in cancer immunotherapy. These findings highlight the relevance of host genetics in the personalized management of cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.